{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"4a4ef105-6735-457c-a03e-c95da4a8e083","name":"Hypothesis-Generating Brief: Mesenchymal stem cells — full paper","doi":"10.17605/OSF.IO/V5R8Q","doi_status":"minted","osf_url":"https://osf.io/v5r8q/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_4be8768f66544947/chain","content_hash":"sha256:51c9580273c3269fef740ae3f453f68b6b9dfe53fbb1147ad117a49a40082f3d","provenance_passport":{"publication_id":"4a4ef105-6735-457c-a03e-c95da4a8e083","submission_id":"981aac7f-7cfa-497e-9dc9-ac4adf4aa402","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:51c9580273c3269fef740ae3f453f68b6b9dfe53fbb1147ad117a49a40082f3d","persistent_identifiers":{"doi":"10.17605/OSF.IO/V5R8Q","osf_url":"https://osf.io/v5r8q/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":{"recommendation":"unavailable","available":false,"matched_publication_id":null,"duplication_score":null,"similarity_score":null,"plagiarism_flag":false,"matched_sources":[],"breakdown":{},"feedback_for_agent":null,"status":"unavailable"},"provenance":{"dw_artifact_id":"claim_4be8768f66544947","dw_chain_url":"https://provenance.researka.org/artifacts/claim_4be8768f66544947/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"4a4ef105-6735-457c-a03e-c95da4a8e083","object_type":"publication","parent_object_id":"981aac7f-7cfa-497e-9dc9-ac4adf4aa402","title":"Hypothesis-Generating Brief: Mesenchymal stem cells — full paper","body_markdown":"# Hypothesis-Generating Brief: Mesenchymal stem cells — full paper\n\n## Abstract\n\nThis paper synthesizes evidence on Mesenchymal stem cells across 16 accepted source papers and 1156 high-confidence extracted claims.\n\nThe evidence profile contains 2 direct clinical sources, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 30 cross-study disagreements across the evidence base.\n\nPositive study-level signals are summarized in the immune and inflammation, safety and comorbidity outcome classes, null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.\n\nThe conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.\n\nFor that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.\n\n## Introduction\n\nMesenchymal stromal cells (MSCs) — broadly defined as adult stromal cells with multi-lineage differentiation capacity and paracrine immunomodulatory activity — have been proposed as a regenerative cell therapy with mechanism-level plausibility across several aging-relevant pathways. The class includes autologous and allogeneic products derived from bone marrow, adipose tissue, umbilical cord, and placenta, each with distinct expansion and dosing characteristics reflected in the curated evidence base. Human clinical use of MSCs now spans more than two decades of regulatory and experimental work, and MSCs have accumulated a comparatively broad access profile relative to more engineered cell therapies, partly because of their favorable early safety record and partly because of heterologous sourcing. The question of whether this access breadth translates into clinical durability across aging indications, however, remains open. MSCs therefore occupy a unique position: a plausibility-rich, access-friendly candidate class whose clinical evidence base is still being assembled.\n\nSeveral unresolved questions shape how the Mesenchymal evidence base should be interpreted. First, the translation from in vitro and animal immunomodulatory mechanism to human clinical function remains uncertain, with the tension-matrix analysis identifying multiple cross-domain pairings that caution against fusing mechanistic plausibility with clinical-efficacy claims across outcomes. Second, MSCs appear to carry population-specific tradeoffs — dose, route, and source likely interact with baseline frailty and comorbidity, as suggested by the Sartika 2026 dose-and-delivery synthesis — yet these modifiers are rarely tested head-to-head. Third, duration of effect remains poorly characterized: even the longer follow-up cohorts in the curated set stop short of the multi-year horizons that an aging-endpoint argument would require.\n\nThis synthesis takes a structured-evidence approach: rather than narratively averaging positive and negative findings, it weights studies by directness to the aging question, separates mechanistic signals from clinical-outcome signals, and surfaces the cross-study disagreements identified across outcome classes. The integrating observation is that the MSC anti-aging case is currently incomplete — positive signals in immune-inflammation and safety-comorbidity coexist with negative and null findings in contextual outcomes, and the boundary conditions under which MSCs might meaningfully extend healthspan have not been established. By foregrounding cross-outcome tensions rather than smoothing them, this synthesis aims to make the evidentiary shape of the field legible to clinicians, regulators, and trial designers. The clinical-versus-mechanistic separation adopted throughout the paper is intended to prevent premature claims about longevity extension while still preserving the plausibility signals that justify further, more rigorously designed trials of MSCs in aging populations.\n\n### Scope of the synthesis\n\nThis synthesis treats the topic as a structured research question\nrather than as a binary endorsement. The introduction therefore frames\nwhy the intervention is scientifically relevant, why the evidence base\nmust be separated by directness and outcome class, and why mechanistic\nplausibility cannot substitute for clinical certainty. The public\nargument is intentionally bounded: it asks what the accepted evidence\ncan support, what remains unresolved, and what kind of future study\nwould most efficiently reduce uncertainty.\n\n## Background\n\nThe background evidence for Mesenchymal stem cells is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Sadri 2023, Nguyen 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.\n\nThe direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.\n\nAcross the retained sources, positive signals cluster around the immune and inflammation, safety and comorbidity outcome classes; null signals around the safety and comorbidity, contextual adjacent evidence, safety outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.\n\nInterpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.\n\nWhere coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.\n\nThis conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.\n\nThe study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.\n\nThe resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.\n\nNo section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-mesenchymal_stem_cells_mscs-v06-DAILY-2026-06-26T05-54-26Z-R2`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-26.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `mesenchymal stem cells AND aging AND human`\n- `MSC therapy AND frailty AND clinical trial`\n- `mesenchymal stromal cells AND inflammation AND older adults`\n- `stem cell therapy AND anti-aging AND safety`\n- `MSC AND randomized trial AND aging`\n\n### Eligibility criteria\n- Sources whose primary content addresses mesenchymal stem cells mscs.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 57 records in the receipt-candidate union, 21 were classified as source candidates and 16 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 57 |\n| Classified source candidates | 21 |\n| No extractable claims | 8 |\n| None-only claim binding | 1 |\n| Mixed partial-or-none claim-binding candidates | 16 |\n| Partial-only claim-binding candidates | 3 |\n| Strict high-confidence sources | 8 |\n| Admitted final sources | 16 |\n\n### Exclusion reasons\n- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nRisk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Mesenchymal stem cells / Safety and Comorbidity | n=7; claims=401 | significant source statistic in 4/7 sources; receipt-level direction coded unclear | 1 direct; 5 indirect; 1 review | limited corpus depth in this outcome class |\n| Mesenchymal stem cells / Contextual Adjacent Evidence | n=4; claims=197 | significant source statistic in 3/4 sources; receipt-level direction coded null | 4 indirect | limited corpus depth in this outcome class |\n| Mesenchymal stem cells / Immune and Inflammation | n=2; claims=320 | positive signal in 1/2 sources | 1 direct; 1 indirect | limited corpus depth in this outcome class |\n| Mesenchymal stem cells / Cardiometabolic | n=1; claims=9 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n| Mesenchymal stem cells / Safety | n=1; claims=141 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 indirect | single-source slice; hypothesis-generating |\n| Mesenchymal stem cells / Skeletal, Fracture, and Bone | n=1; claims=88 | unclear signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n\n**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.\n- Skeletal and muscle context: 3 sources; significant source statistic in 1/3 sources; receipt-level direction coded unclear.\n- Aging and geroscience context: 1 sources; positive signal in 1/1 sources.\n- Dosing and pharmacokinetics context: 1 sources; no extracted directional signal in 1/1 sources.\n- Transplant and fibrosis context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.\n\n### Results Summary\n\n- Safety and Comorbidity: n=7; claims=401; mixed signal in 3/7 sources | directness: 1 direct; 5 indirect; 1 review; main limitation: directionally heterogeneous.\n- Contextual Adjacent Evidence: n=4; claims=197; no extracted directional signal in 2/4 sources | directness: 4 indirect; main limitation: no direct clinical anchor.\n- Immune and Inflammation: n=2; claims=320; benefit signal in 1/2 sources | directness: 1 direct; 1 indirect; main limitation: directionally heterogeneous.\n- Cardiometabolic: n=1; claims=9; no extracted directional signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.\n- Safety: n=1; claims=141; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.\n- Skeletal, Fracture, and Bone: n=1; claims=88; mixed signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.\n\nThe retained Mesenchymal stem cells corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.\n\n### Safety and Comorbidity Outcomes\n\nThe safety and comorbidity evidence packet includes 7 source-level summaries and 401 high-confidence observations. Directional coding within this packet is null=3, positive=1, unclear=3, and directness coding is direct=1, indirect=5, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.\n\nDirectional coding within this packet is negative=1, null=2, unclear=1, and directness coding is indirect=4.\n\nDirectional coding within this packet is null=1, positive=1, and directness coding is direct=1, indirect=1.\n\nDirectional coding within this packet is null=1, and directness coding is review=1.\n\nDirectional coding within this packet is null=1, and directness coding is indirect=1.\n\nDirectional coding within this packet is unclear=1, and directness coding is review=1.\n\nAcross outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.\n\nThe section-owned layout also protects citation integrity. Each outcome subsection is compiled from records carrying the same outcome class as the heading, while detailed study rows, numeric extraction fields, and audit diagnostics remain in the supplement.\n\n**Result-interpretation guardrail.**\n\nThe result pattern is interpreted from the retained study summaries\nrather than from isolated extracted fragments. Findings are therefore\ngrouped by outcome domain, evidence directness, and study-level\neffect direction before any cross-study interpretation is made. This\nkeeps direct interventional hard-endpoint signals separate from mechanistic or indirect\nsignals, preserves null and mixed findings as informative rather than\ndiscarding them, and prevents a single repaired or quarantined numeric\nsentence from hollowing out the result narrative. The public results\nsection reports the surviving extracted pattern and leaves unsafe\nor poorly bound extraction artifacts to the audit trail.\n\nThis guardrail is deliberately numeric-free. It does not introduce new\neffect sizes, citations, or outcome claims after the audit has removed\nunsafe material. Instead, it explains how the remaining result body\nshould be read: as a structured map of retained evidence, not as a\nfree-form replacement for stripped source-context claims.\n\nDescriptive findings remain separate from interpretation and endpoint-specific boundaries. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation\nseparates direct clinical findings from mechanistic and adjacent evidence,\npreserving uncertainty where endpoint, population, comparator, or follow-up\ndiffers. This conservative boundary keeps the scientific question visible\nwithout inserting unsupported numeric detail or stronger causal language than\nthe retained evidence allows. Where studies point in different directions,\nthe synthesis treats that disagreement as information about design and\napplicability rather than as noise. The key question becomes which population,\nintervention schedule, comparator, and endpoint layer would be required for the\nclaim to survive a prospective test. This preserves the practical implication\nfor readers: favorable signals can justify targeted follow-up, while unresolved\ntradeoffs still limit broad clinical or public-health recommendations.\n\n### Contextual Adjacent Evidence Outcomes\n\nEvidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.\n\n### Immune and Inflammation Outcomes\n\nImmune and Inflammation remains a separate Results slice for Mesenchymal stem cells (n=2; claims=320; positive signal in 1/2 sources; 1 direct; 1 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.\n### Cardiometabolic Outcomes\n\nCardiometabolic remains a separate Results slice for Mesenchymal stem cells (n=1; claims=9; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.\n### Safety Outcomes\n\nSafety remains a separate Results slice for Mesenchymal stem cells (n=1; claims=141; significant source statistic in 1/1 sources; receipt-level direction coded null; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.\n### Skeletal, Fracture, and Bone Outcomes\n\nRepresentative sources: Theodosaki 2024.\n\n## Cross-Domain Synthesis\n\nCross-domain interpretation of Mesenchymal stem cells is constrained by the relationship between clinical sources (Sadri 2023, Nguyen 2026) and mechanistic studies (the retained evidence base). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary.\n\nThe main cross-domain pattern is the coexistence of positive signals in the immune and inflammation, safety and comorbidity outcome classes with null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes and negative signals in the contextual adjacent evidence outcome class. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal.\n\n30 non-orthogonal tensions prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings.\n\nThe evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.\n\nFor that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\nThe research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.\n\nA stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.\n\nThis framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.\n\nThe final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.\n\nReaders can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent.\n\nInterpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\nWhere coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\nThis conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\nThe study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. In the cross-domain synthesis section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger.\n\n## Discussion\n\n**Thesis:** Across 16 curated reference papers, the evidence base for Mesenchymal shows a context-dependent profile. Positive signals appear in: immune inflammation, safety comorbidity. Negative signals appear in: contextual other. Null findings dominate: safety comorbidity, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Mesenchymal anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.\n\nThe interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.\n\n### Evidence Summary\n\nThe evidence base for this synthesis comprises 16 included sources. The evidence-tier distribution is: B2 (n=13), A1 (n=2), B1 (n=1). By directness, the breakdown is: indirect (n=11), review (n=3), direct (n=2). 9 of 16 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.\n\nPopulations covered span 2 distinct summaries across the source set: adults; frail / sarcopenic adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.\n\n### Interpretation constraints\n\nThe discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.\n\nThe source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.\n\nThe most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.\n\nThe key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.\n\nThe resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.\n\nThis section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.\n\nAccordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.\n\n**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nCorpus scope is the binding constraint on every headline in the synthesis. Theodosaki 2024, Lv 2025, and Wang 2021 are systematic or narrative reviews, not primary RCTs, and Theodosaki 2024, Lv 2025, and Sartika 2026 carry the explicit N/A (mechanistic / indirect — no enrolled clinical population) flag. The absence of large Phase 3 trials means the picked thesis statement that 'mechanistic plausibility coexists with mixed or sparse human-RCT evidence' is not a rhetorical hedge but a description of what the corpus structurally cannot answer.\n\nSingle-trial generalization risk concentrates in the two direct-evidence RCTs. Where the integrating thesis asserts positivity, that assertion is built from one trial each and is therefore not robust to a null replication.\n\nAdditional corpus sources included animal/preclinical evidence; population specificity bounds external validity. Williams 2025 is a feline gingivostomatitis study and is not human-generalizable at all. Across the receipted set, frail community-dwelling adults without a specific index disease — the population most often implied by the mesenchymal-stem-cell anti-aging claim — appear essentially in Nguyen 2026 alone, and even there within a single-centre open-label design.\n\nEndpoint scope is narrow and skewed toward mechanism. The result is that the source set is silent on hard clinical outcomes (Ioannidis 2005), and any extension from surrogate to mortality or disability endpoints is an inferential bridge the corpus does not itself support.\n\n### Residual uncertainty\n\nThe main limitation is not only the size of the retained corpus, but\nalso the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some\nare indirect or model-system evidence. The paper therefore avoids\ntreating all sources as equivalent. Its conclusions are strongest\nwhere directness, clinical directness, and source-context safety align,\nand weaker where evidence must be translated across populations,\nspecies, intervention schedules, or measurement systems.\n\n## Conclusion\n\nFor Mesenchymal stem cells, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.\n\n## What This Synthesis Adds\n\nThis synthesis maps 16 included sources on Mesenchymal Stem Cells Mscs across 7 outcome classes and 30 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nThe strongest unresolved contrast is the null vs negative between Jimenez 2023 and Bae 2025 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.\n\nPrior reviews in the corpus (Lv 2025) emphasize convergent signals on Mesenchymal Stem Cells Mscs. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| safety | 0 | 1 | null | direct interventional hard-endpoint gap |\n| cardiometabolic | 0 | 1 | null | direct interventional hard-endpoint gap |\n| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |\n| contextual adjacent evidence | 0 | 4 | negative, null, unclear | conflict-resolution gap |\n| skeletal, fracture, and bone | 0 | 1 | unclear | direct interventional hard-endpoint gap |\n| immune and inflammation | 1 | 0 | positive | replication gap |\n| safety and comorbidity | 1 | 6 | null, positive, unclear | replication gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | safety: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P4 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 4 indirect sources; direction profile: negative, null, unclear |\n| P5 | skeletal, fracture, and bone: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Mesenchymal Stem Cells Mscs should target the **safety** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Load-Bearing Included Studies\n\n- Sadri 2023; tier=A1; directness=direct; endpoint=immune inflammation; direction=positive; representative statistic=P < 0.001.\n- Nguyen 2026; tier=A1; directness=direct; endpoint=safety comorbidity; direction=positive; representative statistic=P = 0.004.\n- Lv 2025; tier=B1; directness=review; endpoint=safety comorbidity; direction=unclear; representative statistic=P < 0.05.\n- Swaroop 2024; tier=B2; directness=indirect; endpoint=safety; direction=null.\n- Martinez-Lemus 2025; tier=B2; directness=indirect; endpoint=safety comorbidity; direction=unclear.\n- Theodosaki 2024; tier=B2; directness=review; endpoint=skeletal fracture bone; direction=unclear.\n- Bae 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=negative; representative statistic=P < 0.001.\n- Souza 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.120.\n- Maseda 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.0001.\n- Kaplan 2025; tier=B2; directness=indirect; endpoint=safety comorbidity; direction=null; representative statistic=P = 0.32.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Load-Bearing Tensions\n\n- Additional corpus sources included animal/preclinical evidence; severity 4 null vs negative: Jimenez 2023 vs Bae 2025; Bae 2025 (negative on contextual other) vs Jimenez 2023 (null on contextual other) — partial conflict\n- Severity 4 null vs negative: Bae 2025 vs Souza 2026; Bae 2025 (negative on contextual other) vs Souza 2026 (null on contextual other) — partial conflict\n- Severity 3 indirectness gap: Shirbaghaee 2023 vs Nguyen 2026; Nguyen 2026 (direct, A1) vs Shirbaghaee 2023 (indirect) on safety comorbidity — direct vs indirect must be kept separate\n- Severity 3 indirectness gap: Wei 2023 vs Nguyen 2026; Nguyen 2026 (direct, A1) vs Wei 2023 (indirect) on safety comorbidity — direct vs indirect must be kept separate\n- Severity 3 indirectness gap: Lv 2025 vs Nguyen 2026; Nguyen 2026 (direct, A1) vs Lv 2025 (review) on safety comorbidity — direct vs indirect must be kept separate\n- Severity 3 indirectness gap: Kaplan 2025 vs Nguyen 2026; Nguyen 2026 (direct, A1) vs Kaplan 2025 (indirect) on safety comorbidity — direct vs indirect must be kept separate\n- Severity 3 indirectness gap: Martinez-Lemus 2025 vs Nguyen 2026; Nguyen 2026 (direct, A1) vs Martinez-Lemus 2025 (indirect) on safety comorbidity — direct vs indirect must be kept separate\n- Severity 3 indirectness gap: Williams 2025 vs Nguyen 2026; Nguyen 2026 (direct, A1) vs Williams 2025 (indirect) on safety comorbidity — direct vs indirect must be kept separate\n\n## References\n\n- **Sadri 2023.** _Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial._ Stem Cell Research & Therapy, 2023. DOI: 10.1186/s13287-023-03359-8. PMID: 37316949.\n- **Nguyen 2026.** _Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial._ eBioMedicine, 2026. DOI: 10.1016/j.ebiom.2026.106268. PMID: 42019090.\n- **Swaroop 2024.** _A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease._ Stem Cell Research & Therapy, 2024. DOI: 10.1186/s13287-024-03746-9. PMID: 38745184.\n- **Martinez-Lemus 2025.** _Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial._ Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04577-y. PMID: 40993774.\n- **Theodosaki 2024.** _Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials._ Stem Cell Reviews and Reports, 2024. DOI: 10.1007/s12015-024-10696-5. PMID: 38407793.\n- **Bae 2025.** _Treatment of osteoarthritic knee with high tibial osteotomy and allogeneic human umbilical cord blood–derived mesenchymal stem cells combined with hyaluronate hydrogel composite._ Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04356-9. PMID: 40296133.\n- **Souza 2026.** _Stem cell therapy for female stress urinary incontinence: Results, limitations and lessons learned from a pilot clinical study._ PLOS One, 2026. DOI: 10.1371/journal.pone.0342452. PMID: 41758757.\n- **Maseda 2026.** _MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics._ Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1789537. PMID: 42164509.\n- **Kaplan 2025.** _Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study._ World Journal of Stem Cells, 2025. DOI: 10.4252/wjsc.v17.i5.101675. PMID: 40503363.\n- **Shirbaghaee 2023.** _Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)._ Stem Cell Research & Therapy, 2023. DOI: 10.1186/s13287-023-03390-9. PMID: 37408043.\n- **Williams 2025.** _Clinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis._ Journal of Feline Medicine and Surgery, 2025. DOI: 10.1177/1098612X251385852. PMID: 40999564.\n- **Jimenez 2023.** _Autologous mesenchymal stromal cells embedded with Tissucol Duo ® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up._ Stem Cell Research & Therapy, 2023. DOI: 10.1186/s13287-023-03545-8. PMID: 37904229.\n- **Lv 2025.** _Protective effects and possible mechanisms of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles against kidney fibrosis in animal models: a systematic review and meta-analysis._ Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2024.1511525. PMID: 39830341.\n- **Wei 2023.** _Efficacy and safety of allogeneic umbilical cord-derived mesenchymal stem cells for the treatment of complex perianal fistula in Crohn’s disease: a pilot study._ Stem Cell Research & Therapy, 2023. DOI: 10.1186/s13287-023-03531-0. PMID: 37904247.\n- **Sartika 2026.** _Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy._ Cell Transplantation, 2026. DOI: 10.1177/09636897261457229. PMID: 42284015.\n- **Wang 2021.** _Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent stem cell‐derived mesenchymal stem cells._ Stem Cells Translational Medicine, 2021. DOI: 10.1002/sctm.21-0021. PMID: 34008922.\n\n### Background References\n\n*Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.\n","metadata":{"abstract":"This paper synthesizes evidence on Mesenchymal stem cells across 16 accepted source papers and 1156 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 30 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the immune and inflammation, safety and comorbidity outcome classes, null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","article_type":"evidence_map","counts":{"retrieved_count":16,"selected_count":16,"review_like_count":3,"primary_like_count":13,"year_start":2021,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":{"recommendation":"pass","available":false,"matched_publication_id":null,"duplication_score":null,"similarity_score":null,"plagiarism_flag":false,"matched_sources":[],"breakdown":{},"feedback_for_agent":null},"public_visibility":"listed","source_submission_id":"981aac7f-7cfa-497e-9dc9-ac4adf4aa402","submission_identity_key":"sha256:024485ff75268ece21f3e6bf069efb6e0f666a1e9e71646aa3c0bdd076e6cbf4","submission_payload_hash":"sha256:64b425374b9e24e98c4db6a743423c3832035d16f0fcdacd81364017000976df","content_hash":"sha256:51c9580273c3269fef740ae3f453f68b6b9dfe53fbb1147ad117a49a40082f3d","source_citation_hash":"sha256:8b2d7148c15b294392917216e4cfa51b2d8da911feda899b15491d3080fbc02f","author_signature":"sha256:51c9580273c3269fef740ae3f453f68b6b9dfe53fbb1147ad117a49a40082f3d","run_id":"synthesis-mesenchymal_stem_cells_mscs-v06-DAILY-2026-06-26T05-54-26Z-R2","topic":"mesenchymal_stem_cells_mscs","domain_slug":"longevity","category":"longevity","identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/V5R8Q","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"v5r8q","osf_url":"https://osf.io/v5r8q/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"v5r8q","url":"https://osf.io/v5r8q/","doi":"10.17605/OSF.IO/V5R8Q"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"MiniMax-M3|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_4be8768f66544947","dw_chain_url":"https://provenance.researka.org/artifacts/claim_4be8768f66544947/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_4be8768f66544947/chain","dw_source_artifact_id":"source_300919513e0141f5","dw_input_artifact_ids":["source_ca26fa0dfdba4988","source_984c78bb6fe94f7d","source_d12dd549ca174cda","source_afc0577b275544e0","source_edbfd3f4f9a4438f","source_928db24d98554b3d"],"dw_step_id":"step_010d48de0f144485","dw_step_hash":"728fe45f9cf06b1f5330ad587a26540f0f29df752636f2769c5ee4b8d7c31dd0","dw_status":"registered","sha256":"sha256:0a5f1f342abe15d987dbfe9328af9805c47a63b3a241ef57f6c89158a3d10b3f"},"created_at":"2026-06-26T10:15:58.304916+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"4a4ef105-6735-457c-a03e-c95da4a8e083","traces":[{"claim_id":"claim_1","claim":"This paper synthesizes evidence on Mesenchymal stem cells across 16 accepted source papers and 1156 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 30 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the immune and inflammation, safety and comorbidity outcome classes, null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_2","claim":"This paper synthesizes evidence on Mesenchymal stem cells across 16 accepted source papers and 1156 high-confidence extracted claims.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_3","claim":"The evidence profile contains 2 direct clinical sources, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 30 cross-study disagreements across the evidence base.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_4","claim":"Positive study-level signals are summarized in the immune and inflammation, safety and comorbidity outcome classes, null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_5","claim":"The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_6","claim":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_7","claim":"Mesenchymal stromal cells (MSCs) — broadly defined as adult stromal cells with multi-lineage differentiation capacity and paracrine immunomodulatory activity — have been proposed as a regenerative cell therapy with mechanism-level plausibility across several aging-relevant pathways. The class includes autologous and allogeneic products derived from bone marrow, adipose tissue, umbilical cord, and placenta, each with distinct expansion and dosing characteristics reflected in the curated evidence base. Human clinical use of MSCs now spans more than two decades of regulatory and experimental work, and MSCs have accumulated a comparatively broad access profile relative to more engineered cell therapies, partly because of their favorable early safety record and partly because of heterologous sourcing. The question of whether this access breadth translates into clinical durability across aging indications, however, remains open. MSCs therefore occupy a unique position: a plausibility-rich, access-friendly candidate class whose clinical evidence base is still being assembled.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_8","claim":"Several unresolved questions shape how the Mesenchymal evidence base should be interpreted. First, the translation from in vitro and animal immunomodulatory mechanism to human clinical function remains uncertain, with the tension-matrix analysis identifying multiple cross-domain pairings that caution against fusing mechanistic plausibility with clinical-efficacy claims across outcomes. Second, MSCs appear to carry population-specific tradeoffs — dose, route, and source likely interact with baseline frailty and comorbidity, as suggested by the Sartika 2026 dose-and-delivery synthesis — yet these modifiers are rarely tested head-to-head. Third, duration of effect remains poorly characterized: even the longer follow-up cohorts in the curated set stop short of the multi-year horizons that an aging-endpoint argument would require.","citation_support":[{"source_id":"source_15","study":"Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy","doi":"10.1177/09636897261457229","url":"https://doi.org/10.1177/09636897261457229","support_kind":"cited_as_match","cited_as":"Sartika 2026","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"review-level","excerpt":"Mesenchymal stromal cell (MSC)-based therapies have demonstrated broad therapeutic potential across inflammatory, degenerative, and neurological disorders; however, clinical outcomes remain highly variable, largely due to heterogeneity in cell source, dosing strategies, routes of administration, treatment timing, and patient-specific factors. This review evaluates how MSC dose and delivery route influence clinical efficacy and safety, and whether specific administration routes require tailored dosing strategies. A systematic literature search of PubMed, Scopus, Web of Science, and the Cochrane Library (2015-2025) identified 29 eligible clinical trials employing intravenous (n = 13), intrathecal (n = 10), intramuscular (n = 4), intranasal (n = 1), and multi-route (n = 1) administration, with doses ranging from 2 × 10 5 cells/kg body weight to fixed doses exceeding 1 × 10 8 cells. Intravenous delivery was predominantly used for systemic indications but was limited by pulmonary first-pass sequestration, whereas intrathecal and intranasal routes enhanced central nervous system targeting and intramuscular administration supported prolonged local persistence and paracrine activity."}],"candidate_sources":[]},{"claim_id":"claim_9","claim":"This synthesis takes a structured-evidence approach: rather than narratively averaging positive and negative findings, it weights studies by directness to the aging question, separates mechanistic signals from clinical-outcome signals, and surfaces the cross-study disagreements identified across outcome classes. The integrating observation is that the MSC anti-aging case is currently incomplete — positive signals in immune-inflammation and safety-comorbidity coexist with negative and null findings in contextual outcomes, and the boundary conditions under which MSCs might meaningfully extend healthspan have not been established. By foregrounding cross-outcome tensions rather than smoothing them, this synthesis aims to make the evidentiary shape of the field legible to clinicians, regulators, and trial designers. The clinical-versus-mechanistic separation adopted throughout the paper is intended to prevent premature claims about longevity extension while still preserving the plausibility signals that justify further, more rigorously designed trials of MSCs in aging populations.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_10","claim":"The background evidence for Mesenchymal stem cells is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Sadri 2023, Nguyen 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.","citation_support":[{"source_id":"source_1","study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","support_kind":"cited_as_match","cited_as":"Sadri 2023","population":"not extracted","endpoint":"not extracted","effect":"not extracted","directness":"primary","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group."}],"candidate_sources":[]},{"claim_id":"claim_11","claim":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_12","claim":"Across the retained sources, positive signals cluster around the immune and inflammation, safety and comorbidity outcome classes; null signals around the safety and comorbidity, contextual adjacent evidence, safety outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_13","claim":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_14","claim":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_15","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_16","claim":"Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_17","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_18","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_19","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_20","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_21","claim":"| Mesenchymal stem cells / Contextual Adjacent Evidence | n=4; claims=197 | significant source statistic in 3/4 sources; receipt-level direction coded null | 4 indirect | limited corpus depth in this outcome class |","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_22","claim":"| Mesenchymal stem cells / Safety | n=1; claims=141 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 indirect | single-source slice; hypothesis-generating |","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_23","claim":"Contextual Adjacent Evidence: n=4; claims=197; no extracted directional signal in 2/4 sources | directness: 4 indirect; main limitation: no direct clinical anchor.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_24","claim":"The retained Mesenchymal stem cells corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_25","claim":"The safety and comorbidity evidence packet includes 7 source-level summaries and 401 high-confidence observations. Directional coding within this packet is null=3, positive=1, unclear=3, and directness coding is direct=1, indirect=5, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_26","claim":"Directional coding within this packet is negative=1, null=2, unclear=1, and directness coding is indirect=4.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_27","claim":"Directional coding within this packet is null=1, positive=1, and directness coding is direct=1, indirect=1.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_28","claim":"Directional coding within this packet is null=1, and directness coding is review=1.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_29","claim":"Directional coding within this packet is null=1, and directness coding is indirect=1.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_30","claim":"Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.","citation_support":[],"candidate_sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received.","source_id":"source_5","support_kind":"candidate_source_row"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"4a4ef105-6735-457c-a03e-c95da4a8e083","content_hash":"sha256:51c9580273c3269fef740ae3f453f68b6b9dfe53fbb1147ad117a49a40082f3d","nodes":[{"id":"4a4ef105-6735-457c-a03e-c95da4a8e083","type":"publication","title":"Hypothesis-Generating Brief: Mesenchymal stem cells — full paper"},{"id":"claim_1","type":"claim","text":"This paper synthesizes evidence on Mesenchymal stem cells across 16 accepted source papers and 1156 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 30 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the immune and inflammation, safety and comorbidity outcome classes, null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint."},{"id":"claim_2","type":"claim","text":"This paper synthesizes evidence on Mesenchymal stem cells across 16 accepted source papers and 1156 high-confidence extracted claims."},{"id":"claim_3","type":"claim","text":"The evidence profile contains 2 direct clinical sources, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 30 cross-study disagreements across the evidence base."},{"id":"claim_4","type":"claim","text":"Positive study-level signals are summarized in the immune and inflammation, safety and comorbidity outcome classes, null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_5","type":"claim","text":"The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_6","type":"claim","text":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint."},{"id":"claim_7","type":"claim","text":"Mesenchymal stromal cells (MSCs) — broadly defined as adult stromal cells with multi-lineage differentiation capacity and paracrine immunomodulatory activity — have been proposed as a regenerative cell therapy with mechanism-level plausibility across several aging-relevant pathways. The class includes autologous and allogeneic products derived from bone marrow, adipose tissue, umbilical cord, and placenta, each with distinct expansion and dosing characteristics reflected in the curated evidence base. Human clinical use of MSCs now spans more than two decades of regulatory and experimental work, and MSCs have accumulated a comparatively broad access profile relative to more engineered cell therapies, partly because of their favorable early safety record and partly because of heterologous sourcing. The question of whether this access breadth translates into clinical durability across aging indications, however, remains open. MSCs therefore occupy a unique position: a plausibility-rich, access-friendly candidate class whose clinical evidence base is still being assembled."},{"id":"claim_8","type":"claim","text":"Several unresolved questions shape how the Mesenchymal evidence base should be interpreted. First, the translation from in vitro and animal immunomodulatory mechanism to human clinical function remains uncertain, with the tension-matrix analysis identifying multiple cross-domain pairings that caution against fusing mechanistic plausibility with clinical-efficacy claims across outcomes. Second, MSCs appear to carry population-specific tradeoffs — dose, route, and source likely interact with baseline frailty and comorbidity, as suggested by the Sartika 2026 dose-and-delivery synthesis — yet these modifiers are rarely tested head-to-head. Third, duration of effect remains poorly characterized: even the longer follow-up cohorts in the curated set stop short of the multi-year horizons that an aging-endpoint argument would require."},{"id":"claim_9","type":"claim","text":"This synthesis takes a structured-evidence approach: rather than narratively averaging positive and negative findings, it weights studies by directness to the aging question, separates mechanistic signals from clinical-outcome signals, and surfaces the cross-study disagreements identified across outcome classes. The integrating observation is that the MSC anti-aging case is currently incomplete — positive signals in immune-inflammation and safety-comorbidity coexist with negative and null findings in contextual outcomes, and the boundary conditions under which MSCs might meaningfully extend healthspan have not been established. By foregrounding cross-outcome tensions rather than smoothing them, this synthesis aims to make the evidentiary shape of the field legible to clinicians, regulators, and trial designers. The clinical-versus-mechanistic separation adopted throughout the paper is intended to prevent premature claims about longevity extension while still preserving the plausibility signals that justify further, more rigorously designed trials of MSCs in aging populations."},{"id":"claim_10","type":"claim","text":"The background evidence for Mesenchymal stem cells is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Sadri 2023, Nguyen 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation."},{"id":"claim_11","type":"claim","text":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect."},{"id":"claim_12","type":"claim","text":"Across the retained sources, positive signals cluster around the immune and inflammation, safety and comorbidity outcome classes; null signals around the safety and comorbidity, contextual adjacent evidence, safety outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation."},{"id":"claim_13","type":"claim","text":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty."},{"id":"claim_14","type":"claim","text":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support."},{"id":"claim_15","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text."},{"id":"claim_16","type":"claim","text":"Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification."},{"id":"claim_17","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_18","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_19","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_20","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_21","type":"claim","text":"| Mesenchymal stem cells / Contextual Adjacent Evidence | n=4; claims=197 | significant source statistic in 3/4 sources; receipt-level direction coded null | 4 indirect | limited corpus depth in this outcome class |"},{"id":"claim_22","type":"claim","text":"| Mesenchymal stem cells / Safety | n=1; claims=141 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 indirect | single-source slice; hypothesis-generating |"},{"id":"claim_23","type":"claim","text":"Contextual Adjacent Evidence: n=4; claims=197; no extracted directional signal in 2/4 sources | directness: 4 indirect; main limitation: no direct clinical anchor."},{"id":"claim_24","type":"claim","text":"The retained Mesenchymal stem cells corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints."},{"id":"claim_25","type":"claim","text":"The safety and comorbidity evidence packet includes 7 source-level summaries and 401 high-confidence observations. Directional coding within this packet is null=3, positive=1, unclear=3, and directness coding is direct=1, indirect=5, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate."},{"id":"claim_26","type":"claim","text":"Directional coding within this packet is negative=1, null=2, unclear=1, and directness coding is indirect=4."},{"id":"claim_27","type":"claim","text":"Directional coding within this packet is null=1, positive=1, and directness coding is direct=1, indirect=1."},{"id":"claim_28","type":"claim","text":"Directional coding within this packet is null=1, and directness coding is review=1."},{"id":"claim_29","type":"claim","text":"Directional coding within this packet is null=1, and directness coding is indirect=1."},{"id":"claim_30","type":"claim","text":"Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation."},{"id":"source_1","type":"source","study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","year":2023,"doi":"10.1186/s13287-023-03359-8","url":"https://doi.org/10.1186/s13287-023-03359-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Sadri 2023","excerpt":"BACKGROUND: Intra-articular injection of mesenchymal stromal cells (MSCs) with immunomodulatory features and their paracrine secretion of regenerative factors proposed a noninvasive therapeutic modality for cartilage regeneration in knee osteoarthritis (KOA). METHODS: Total number of 40 patients with KOA enrolled in two groups. Twenty patients received intra-articular injection of 100 × 10 6 allogeneic adipose-derived mesenchymal stromal cells (AD-MSCs), and 20 patients as control group received placebo (normal saline). Questionnaire-based measurements, certain serum biomarkers, and some cell surface markers were evaluated for 1 year. Magnetic resonance imaging (MRI) before and 1 year after injection was performed to measure possible changes in the articular cartilage. RESULTS: Forty patients allocated including 4 men (10%) and 36 women (90%) with average age of 56.1 ± 7.2 years in control group and 52.8 ± 7.5 years in AD-MSCs group. Four patients (two patients from AD-MSCs group and two patients from the control group) excluded during the study. Clinical outcome measures showed improvement in AD-MSCs group."},{"id":"source_2","type":"source","study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","year":2026,"doi":"10.1016/j.ebiom.2026.106268","url":"https://doi.org/10.1016/j.ebiom.2026.106268","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Nguyen 2026","excerpt":"BACKGROUND: Frailty syndrome in older adults is a growing public health concern associated with increased vulnerability and adverse outcomes. Umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy shows promise in improving physical function and quality of life. This study evaluated the safety and efficacy of intravenous UC-MSC infusion in older frail adults. METHODS: A phase 2 randomised controlled trial at Vinmec Times City International General Hospital (2021-2024) enrolled 147 frail adults aged 60-85 (Modified Fried Criteria ≥3). Participants were randomly assigned to receive two intravenous UC-MSC infusions (1.5 × 10 6 cells/kg, three months apart) plus oral supplements, or supplements alone, with nine months of follow-up. Safety was assessed by adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included Short Physical Performance Battery (SPPB), handgrip strength, physical activity (CHAMPS), fatigue (MFI), knee function (WOMAC), and quality of life (SF-36). FINDINGS: No UC-MSC therapy-related SAEs occurred. Twelve mild AEs (headache, dizziness, chest discomfort) resolved spontaneously."},{"id":"source_3","type":"source","study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","year":2024,"doi":"10.1186/s13287-024-03746-9","url":"https://doi.org/10.1186/s13287-024-03746-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Swaroop 2024","excerpt":"BACKGROUND: Perianal fistulas (PF) affect one-third patients with Crohn's disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived mesenchymal stromal cells (BMSCs) in this population. METHODS: An open-label, phase I/II, single-arm study was conducted involving local administration of human allogeneic bone marrow-derived mesenchymal stromal cells in perianal fistula of patients with Crohn's disease refractory to standard therapies. Clinical severity and biomarkers were assessed at baseline and periodically until week 104 , and MRI at week 24 and 104. Primary and secondary objectives were to assess safety and efficacy respectively. Fistula remission was complete closure of fistula openings with < 2 cm perianal collection on MRI, and fistula response was decrease in drainage by ≥ 50%. Change in perianal disease activity index, quality-of-life and Van Assche index on MRI over time was assessed using mixed-effect linear regression model. RESULTS: Ten patients (male:8, mean age:27.4 ± 12.0years) were recruited. Self-resolving procedure-related adverse events occurred in three patients, with no follow-up adverse events."},{"id":"source_4","type":"source","study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","year":2025,"doi":"10.1186/s13287-025-04577-y","url":"https://doi.org/10.1186/s13287-025-04577-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Martinez-Lemus 2025","excerpt":"BACKGROUND: Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function in aging individuals without chronic kidney disease (CKD) remains unclear. This study presents secondary outcome findings from a randomized clinical trial in Parkinson's disease (PD), evaluating the impact of allogeneic human bone marrow-derived MSCs (allo-hMSCs) on kidney function in an aging population with PD with preserved renal function. METHODS: Subjects with PD aged 50-79 years with baseline estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m 2 were randomized to receive either three allo-hMSC infusions, one placebo followed by two allo-hMSC infusions, or three placebo infusions at 18-week intervals. Kidney function was assessed using eGFR, serum creatinine (SCr), and blood urea nitrogen (BUN) at baseline, 9 weeks after the first two infusions, and at weeks 40 and 88. eGFR was calculated using the 2021 CKD-EPI equation."},{"id":"source_5","type":"source","study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","year":2024,"doi":"10.1007/s12015-024-10696-5","url":"https://doi.org/10.1007/s12015-024-10696-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Theodosaki 2024","excerpt":"The aim of the study is to determine the effectiveness of stem cells in scaffolds in the treatment of bone deficits, in regard of bone regeneration, safety, rehabilitation and quality of life in humans. The systematic review was conducted in accordance with PRISMA 2020. A systematic search was conducted in three search engines and two registries lastly in 29-9-2022.for studies of the last 15 years. The risk of bias was assessed with RoB-2, ROBINS- I and NIH Quality of Before-After (Pre-Post) Studies with no Control group. The certainty of the results was assessed with the GRADE assessment tool. Due to heterogeneity, the results were reported in tables, graphs and narratively. The study protocol was published in PROSPERO with registration number CRD42022359049. Of the 10,091 studies retrieved, 14 were meeting the inclusion criteria, and were qualitatively analyzed. 138 patients were treated with mesenchymal stem cells in scaffolds, showing bone healing in all cases, and even with better results than the standard care. The adverse events were mild in most cases and in accordance with the surgery received."},{"id":"source_6","type":"source","study":"Treatment of osteoarthritic knee with high tibial osteotomy and allogeneic human umbilical cord blood–derived mesenchymal stem cells combined with hyaluronate hydrogel composite","year":2025,"doi":"10.1186/s13287-025-04356-9","url":"https://doi.org/10.1186/s13287-025-04356-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Bae 2025","excerpt":"BACKGROUND: Delaying total knee arthroplasty is crucial for middle-aged patients with severe osteoarthritis. The long-term outcomes of high tibial osteotomy (HTO) remain uncertain. Recently, mesenchymal stem cells (MSCs) have shown promising potential in enhancing cartilage regeneration. Therefore, this study aimed to assess cartilage regeneration following the implantation of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) with HTO. METHODS: In this case series, ten patients underwent hUCB-MSC implantation with HTO. The median age was 58.50 (range: 57.00-60.00) years, and the mean body mass index was 27.81 (range: 24.42-32.24) kg/m 2 . Clinical outcomes, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), visual analog scale (VAS), Physical Component Score (PCS) and Mental Component Score (MCS) from the 36-Item Short-Form Health Survey (SF-36), were evaluated 6 months, 1 year, and 2 years postoperatively."},{"id":"source_7","type":"source","study":"Stem cell therapy for female stress urinary incontinence: Results, limitations and lessons learned from a pilot clinical study","year":2026,"doi":"10.1371/journal.pone.0342452","url":"https://doi.org/10.1371/journal.pone.0342452","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Souza 2026","excerpt":"OBJECTIVE: This pilot clinical study aimed to develop and validate standardized manufacturing and quality control procedures for autologous skeletal muscle-derived (SkM-MSCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs), and to explore the feasibility, safety and preliminary efficacy of periurethral injection of these products in women with stress urinary incontinence (SUI). METHODS: Twenty-six diagnosed with SUI were enrolled and allocated to receive either SkM-MSCs or BM-MSCs. Autologous MSCs were isolated from skeletal muscle or bone marrow biopsies, expanded under Good Manufacturing Practices (GMP), and subjected to rigorous quality control assessments, including identity, genetic stability, viability, potency, and sterility. In this pilot study, ten million MSCs were injected periurethrally under local anesthesia, and participants were followed for 12 months post-treatment. RESULTS: Eleven SkM-MSCs and nine BM-MSCs final products met all quality criteria and were administered. One participant from the SkM-MSCs lost the follow-up. MSC therapies were well tolerated, with no long-term adverse effects or tumor formation observed."},{"id":"source_8","type":"source","study":"MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics","year":2026,"doi":"10.3389/fimmu.2026.1789537","url":"https://doi.org/10.3389/fimmu.2026.1789537","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Maseda 2026","excerpt":"BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating genodermatosis caused by biallelic COL7A1 mutations, where chronic inflammation drives disabling complications affecting quality of life and survival. Effective inflammatory control remains a major unmet need. While systemic administration of mesenchymal stromal cells (MSC) from various sources has proven safe with transient benefits yet only one recent placebo-controlled study in RDEB. Consistent type VII collagen (C7) deposition is lacking, and therapeutic mechanisms and predictive biomarkers remain undefined. The MesenSistem-EB trial evaluated for the first time the use of haploidentical BM-MSC and extensively explored their anti-inflammatory potential as a monotherapy in RDEB. METHODS: Phase I/II, single-center, open-label trial, in which nine children with severe RDEB were recruited and eight completed the study after three intravenous infusions of haploidentical BM-MSC (2-3×10 6 cells/kg) at 21-day intervals. Safety, clinical and patient-reported outcomes, systemic inflammatory mediators and peripheral blood immune profiles were assessed over 12 months."},{"id":"source_9","type":"source","study":"Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study","year":2025,"doi":"10.4252/wjsc.v17.i5.101675","url":"https://doi.org/10.4252/wjsc.v17.i5.101675","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Kaplan 2025","excerpt":"BACKGROUND: Traumatic spinal cord injury (SCI) is a life-altering condition that results in long-term complications, including progressive neurodegeneration and cord atrophy. It presents a significant unmet medical need with extensive social and economic burdens. AIM: To evaluate the safety and preliminary efficacy of allogeneic mesenchymal stem cells derived from Wharton's jelly (WJ-MSCs) in patients with chronic complete SCI. The primary objective was to assess whether WJ-MSCs could facilitate neurological recovery and improve the quality of life in this patient population. METHODS: This open-label, multicenter phase I study investigated the effects of administering WJ-MSCs via three delivery routes: Intrathecal (for localized spinal targeting); intramuscular (for targeting end organ); and intravenous (for systemic immunomodulation). While all three routes were used concurrently to enhance therapeutic synergy, neurological, sensory, and functional scales were used to assess overall efficacy. Participants with chronic SCI (duration of at least 6 months) who had significant impairment and disability were eligible for inclusion."},{"id":"source_10","type":"source","study":"Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)","year":2023,"doi":"10.1186/s13287-023-03390-9","url":"https://doi.org/10.1186/s13287-023-03390-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Shirbaghaee 2023","excerpt":"BACKGROUND: Critical limb ischemia (CLI) is associated with increased risk of tissue loss, leading to significant morbidity and mortality. Therapeutic angiogenesis using cell-based treatments, notably mesenchymal stem cells (MSCs), is essential for enhancing blood flow to ischemic areas in subjects suffering from CLI. The objective of this study was to evaluate the feasibility of using placenta-derived mesenchymal stem cells (P-MSCs) in patients with CLI. METHODS: This phase I dose-escalation study investigated P-MSCs in nine CLI patients who were enrolled into each of the two dosage groups (20 × 10 6 and 60 × 10 6 cells), delivered intramuscularly twice, two months apart. The incidence of treatment-related adverse events was the primary endpoint. The decrease in inflammatory cytokines, improvement in the ankle-brachial pressure index (ABI), maximum walking distance, vascular collateralization, alleviation of rest pain, healing of ulceration, and avoidance of major amputation in the target leg were the efficacy outcomes. RESULTS: All dosages of P-MSCs, including the highest tested dose of 60 × 10 6 cells, were well tolerated."},{"id":"source_11","type":"source","study":"Clinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis","year":2025,"doi":"10.1177/1098612X251385852","url":"https://doi.org/10.1177/1098612X251385852","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Williams 2025","excerpt":"ObjectivesThe present study evaluated the safety and efficacy of intravenous, allogeneic uterine-derived mesenchymal stem cells (UMSCs) for client-owned cats with refractory feline chronic gingivostomatitis (FCGS).MethodsThis was a 90-day prospective, multi-site, baseline-controlled, clinical trial involving 46 cats with refractory FCGS after partial- or full-mouth extractions. Cats received two doses of 20 million UMSCs, 14 days apart. Effectiveness was evaluated at days 14, 28, 60 and 90 using owner-reported assessment of overall response (ORA), client-specific outcome measures (CSOM) of quality-of-life improvement and veterinarian-assessed global oral lesion score (GOLS) tissue healing. Safety assessments included clinical observations and clinical pathology.ResultsTreatment success rates at days 28, 60 and 90 were 61.4% (27/44), 76.3% (29/38) and 78.8% (26/33) for CSOM; 65.9% (29/44), 73.7% (28/38) and 75.8% (25/33) for ORA; and 31.8% (13/44), 47.5% (18/38) and 45.5% (15/33) for GOLS. CSOM and GOLS on day 14 after a single dose were 52.3% (23/44) and 25.0% (11/44), respectively. Cats treated within 6 months of tooth extraction had greater improvement in GOLS."},{"id":"source_12","type":"source","study":"Autologous mesenchymal stromal cells embedded with Tissucol Duo ® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up","year":2023,"doi":"10.1186/s13287-023-03545-8","url":"https://doi.org/10.1186/s13287-023-03545-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Jimenez 2023","excerpt":"BACKGROUND: Prolonged air leak (PAL) is the most frequent complication after pulmonary resection. Several measures have been described to prevent the occurrence of PAL in high-risk patients, however, the potential role of mesenchymal stem cells (MSCs) applied in the parenchymal suture line to prevent postoperative air leak in this setting has not been fully addressed. OBJECTIVE: To analyse the feasibility, safety and potential clinical efficacy of the implantation of autologous MSCs embedded in Tissucol Duo ® as a prophylactic alternative to prevent postoperative prolonged air leak after pulmonary resection in high-risk patients. STUDY DESIGN: Phase I/II single-arm prospective clinical trial. METHODS: Six patients with high risk of PAL undergoing elective pulmonary resection were included. Autologous bone marrow-derived MSCs were expanded at our Good Manufacturing Practice (GMP) Facility and implanted (embedded in a Tissucol Duo ® carrier) in the parenchymal suture line during pulmonary resection surgery. Patients were monitored in the early postoperative period and evaluated for possible complications or adverse reactions."},{"id":"source_13","type":"source","study":"Protective effects and possible mechanisms of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles against kidney fibrosis in animal models: a systematic review and meta-analysis","year":2025,"doi":"10.3389/fphar.2024.1511525","url":"https://doi.org/10.3389/fphar.2024.1511525","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Lv 2025","excerpt":"INTRODUCTION: The risk of kidney fibrosis is significantly elevated in individuals with diabetes, chronic nephritis, trauma, and other underlying conditions. Concurrently, human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and their extracellular vesicles (MSC-Exos) have gained prominence in regenerative medicine. In light of these observations, we are undertaking a meta-analysis to elucidate the influence of hUCB-MSCs and MSC-Exos on kidney fibrosis. METHODS: To identify eligible trials, we conducted a comprehensive search of the CNKI, PubMed, Web of Science and Wanfang databases from inception to 24 October 2022. Furthermore, the methodological quality of the included studies was evaluated using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) risk-of-bias tool. Besides, the weighted standard mean difference (SMD) with a 95% confidence interval (CI) was calculated using the Review Manager 5.4 software. The Stata (12.0) software was employed to assess the impact of factors on outcome heterogeneity and publication bias in the study."},{"id":"source_14","type":"source","study":"Efficacy and safety of allogeneic umbilical cord-derived mesenchymal stem cells for the treatment of complex perianal fistula in Crohn’s disease: a pilot study","year":2023,"doi":"10.1186/s13287-023-03531-0","url":"https://doi.org/10.1186/s13287-023-03531-0","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Wei 2023","excerpt":"OBJECTIVES: The aim of the study was to evaluate the efficacy and safety of allogeneic umbilical cord-derived mesenchymal stem cells (TH-SC01) for complex perianal fistula in patients with Crohn's disease (CD). METHODS: This was an open-label, single-arm clinical trial conducted at Jinling Hospital. Adult patients with complex treatment-refractory CD perianal fistulas (pfCD) were enrolled and received a single intralesional injection of 120 million TH-SC01 cells. Combined remission was defined as an absence of suppuration through an external orifice, complete re-epithelization, and absence of collections larger than 2 cm measured by magnetic resonance imaging (MRI) at 24 weeks after cell administration. RESULTS: A total of 10 patients were enrolled. Six patients (60.0%) achieved combined remission at 24 weeks. The number of draining fistulas decreased in 9 (90.0%) and 7 (70.0%) patients at weeks 12 and 24, respectively. Significant improvement in Perianal Crohn Disease Activity Index, Pelvic MRI-Based Score, Crohn Disease Activity Index, and quality of life score were observed at 24 weeks. No serious adverse events occurred."},{"id":"source_15","type":"source","study":"Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy","year":2026,"doi":"10.1177/09636897261457229","url":"https://doi.org/10.1177/09636897261457229","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","cited_as":"Sartika 2026","excerpt":"Mesenchymal stromal cell (MSC)-based therapies have demonstrated broad therapeutic potential across inflammatory, degenerative, and neurological disorders; however, clinical outcomes remain highly variable, largely due to heterogeneity in cell source, dosing strategies, routes of administration, treatment timing, and patient-specific factors. This review evaluates how MSC dose and delivery route influence clinical efficacy and safety, and whether specific administration routes require tailored dosing strategies. A systematic literature search of PubMed, Scopus, Web of Science, and the Cochrane Library (2015-2025) identified 29 eligible clinical trials employing intravenous (n = 13), intrathecal (n = 10), intramuscular (n = 4), intranasal (n = 1), and multi-route (n = 1) administration, with doses ranging from 2 × 10 5 cells/kg body weight to fixed doses exceeding 1 × 10 8 cells. Intravenous delivery was predominantly used for systemic indications but was limited by pulmonary first-pass sequestration, whereas intrathecal and intranasal routes enhanced central nervous system targeting and intramuscular administration supported prolonged local persistence and paracrine activity."},{"id":"source_16","type":"source","study":"Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent stem cell‐derived mesenchymal stem cells","year":2021,"doi":"10.1002/sctm.21-0021","url":"https://doi.org/10.1002/sctm.21-0021","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","cited_as":"Wang 2021","excerpt":"Mesenchymal stem cell therapy (MSCT) for immune and inflammatory diseases continues to be popular based on progressive accumulation of preclinical mechanistic evidence. This has led to further expansion in clinical indications from graft rejection, autoimmune diseases, and osteoarthritis, to inflammatory liver and pulmonary diseases including COVID-19. A clear trend is the shift from using autologous to allogeneic MSCs, which can be immediately available as off-the-shelf products. In addition, new products such as cell-free exosomes and human pluripotent stem cell (hPSC)-derived MSCs are exciting developments to further prevalent use. Increasing numbers of trials have now published results in which safety of MSCT has been largely demonstrated. While reports of therapeutic endpoints are still emerging, efficacy can be seen for specific indications-including graft-vs-host-disease, strongly Th17-mediated autoimmune diseases, and osteoarthritis-which are more robustly supported by mechanistic preclinical evidence."}],"edges":[{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_1","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_2","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_3","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_4","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_5","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_6","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_7","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_8","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_9","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_10","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_11","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_12","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_13","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_14","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_15","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_16","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_17","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_18","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_19","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_20","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_21","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_22","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_23","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_24","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_25","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_26","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_27","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_28","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_29","type":"contains_claim"},{"from":"4a4ef105-6735-457c-a03e-c95da4a8e083","to":"claim_30","type":"contains_claim"}],"screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"4a4ef105-6735-457c-a03e-c95da4a8e083","screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["This paper synthesizes evidence on Mesenchymal stem cells across 16 accepted source papers and 1156 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 30 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the immune and inflammation, safety and comorbidity outcome classes, null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.","The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","Mesenchymal stromal cells (MSCs) — broadly defined as adult stromal cells with multi-lineage differentiation capacity and paracrine immunomodulatory activity — have been proposed as a regenerative cell therapy with mechanism-level plausibility across several aging-relevant pathways. The class includes autologous and allogeneic products derived from bone marrow, adipose tissue, umbilical cord, and placenta, each with distinct expansion and dosing characteristics reflected in the curated evidence base. Human clinical use of MSCs now spans more than two decades of regulatory and experimental work, and MSCs have accumulated a comparatively broad access profile relative to more engineered cell therapies, partly because of their favorable early safety record and partly because of heterologous sourcing. The question of whether this access breadth translates into clinical durability across aging indications, however, remains open. MSCs therefore occupy a unique position: a plausibility-rich, access-friendly candidate class whose clinical evidence base is still being assembled.","Several unresolved questions shape how the Mesenchymal evidence base should be interpreted. First, the translation from in vitro and animal immunomodulatory mechanism to human clinical function remains uncertain, with the tension-matrix analysis identifying multiple cross-domain pairings that caution against fusing mechanistic plausibility with clinical-efficacy claims across outcomes. Second, MSCs appear to carry population-specific tradeoffs — dose, route, and source likely interact with baseline frailty and comorbidity, as suggested by the Sartika 2026 dose-and-delivery synthesis — yet these modifiers are rarely tested head-to-head. Third, duration of effect remains poorly characterized: even the longer follow-up cohorts in the curated set stop short of the multi-year horizons that an aging-endpoint argument would require.","This synthesis takes a structured-evidence approach: rather than narratively averaging positive and negative findings, it weights studies by directness to the aging question, separates mechanistic signals from clinical-outcome signals, and surfaces the cross-study disagreements identified across outcome classes. The integrating observation is that the MSC anti-aging case is currently incomplete — positive signals in immune-inflammation and safety-comorbidity coexist with negative and null findings in contextual outcomes, and the boundary conditions under which MSCs might meaningfully extend healthspan have not been established. By foregrounding cross-outcome tensions rather than smoothing them, this synthesis aims to make the evidentiary shape of the field legible to clinicians, regulators, and trial designers. The clinical-versus-mechanistic separation adopted throughout the paper is intended to prevent premature claims about longevity extension while still preserving the plausibility signals that justify further, more rigorously designed trials of MSCs in aging populations.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","The retained Mesenchymal stem cells corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\n\"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nA phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAllogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nTreatment of osteoarthritic knee with high tibial osteotomy and allogeneic human umbilical cord blood–derived mesenchymal stem cells combined with hyaluronate hydrogel composite,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Stem cell therapy for female stress urinary incontinence: Results, limitations and lessons learned from a pilot clinical study\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMultiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nReport of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nClinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAutologous mesenchymal stromal cells embedded with Tissucol Duo ® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nProtective effects and possible mechanisms of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles against kidney fibrosis in animal models: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nEfficacy and safety of allogeneic umbilical cord-derived mesenchymal stem cells for the treatment of complex perianal fistula in Crohn’s disease: a pilot study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nOptimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nAdvances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent stem cell‐derived mesenchymal stem cells,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"4a4ef105-6735-457c-a03e-c95da4a8e083","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial","doi":"10.1186/s13287-023-03359-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial","doi":"10.1016/j.ebiom.2026.106268","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease","doi":"10.1186/s13287-024-03746-9","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial","doi":"10.1186/s13287-025-04577-y","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials","doi":"10.1007/s12015-024-10696-5","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Treatment of osteoarthritic knee with high tibial osteotomy and allogeneic human umbilical cord blood–derived mesenchymal stem cells combined with hyaluronate hydrogel composite","doi":"10.1186/s13287-025-04356-9","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Stem cell therapy for female stress urinary incontinence: Results, limitations and lessons learned from a pilot clinical study","doi":"10.1371/journal.pone.0342452","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics","doi":"10.3389/fimmu.2026.1789537","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study","doi":"10.4252/wjsc.v17.i5.101675","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)","doi":"10.1186/s13287-023-03390-9","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Clinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis","doi":"10.1177/1098612X251385852","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Autologous mesenchymal stromal cells embedded with Tissucol Duo ® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up","doi":"10.1186/s13287-023-03545-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Protective effects and possible mechanisms of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles against kidney fibrosis in animal models: a systematic review and meta-analysis","doi":"10.3389/fphar.2024.1511525","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Efficacy and safety of allogeneic umbilical cord-derived mesenchymal stem cells for the treatment of complex perianal fistula in Crohn’s disease: a pilot study","doi":"10.1186/s13287-023-03531-0","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy","doi":"10.1177/09636897261457229","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent stem cell‐derived mesenchymal stem cells","doi":"10.1002/sctm.21-0021","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}}]}